Loading company…
Pro Abtech develops biopharmaceutical technologies and treatments for obesity, diabetes, and cancer.
Founded in 2017 and based in Gwangju, South Korea, Pro Abtech develops technologies intended to address limitations in biopharmaceutical drugs. In February 2024, it raised KRW 3 billion from BNC Korea and Hanwha Investment & Securities to work with Korea BNC on treatments for obesity, diabetes, and cancer.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in